Form 4: NeuroPace Director Renee Ryan Granted Stock Options Valued at $13.15 Per Share

NeuroPace Inc. Director Renee Ryan was granted 8,745 stock options with an exercise price of $13.15 per share, vesting over 12 months.

Summary

• Renee Ryan, a Director at NeuroPace Inc. (NPCE), was granted 8,745 stock options on June 6, 2025.
• The stock options have an exercise price of $13.15 per share.
• These options will vest in twelve equal consecutive monthly installments, contingent upon Ms. Ryan's continuous service.
• The options are exercisable starting from the vesting dates and expire on June 5, 2035.
• Following this transaction, Ms. Ryan beneficially owns 8,745 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine insider transaction (equity grant) which is generally positive as it aligns director interests with shareholders. It does not contain any negative financial or operational news.

Positives

• The grant of stock options to Director Renee Ryan aligns her interests with those of the shareholders, as the value of her compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for attracting and retaining experienced board members.

Risks

• The value of the granted stock options is subject to market fluctuations; if NeuroPace's stock price does not exceed the exercise price of $13.15, the options may not be 'in the money' and could expire worthless.
• The vesting schedule requires continuous service, meaning the options could be forfeited if the director's service terminates before full vesting.

Future Outlook

The document primarily reports a past transaction and does not contain explicit forward-looking statements regarding company performance or financial guidance, beyond the vesting schedule of the granted options.

Industry Context

The granting of stock options to directors is a common form of executive and board compensation across various industries, particularly in technology and medical device sectors like NeuroPace, to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors, such as Renee Ryan, is a widely accepted compensation strategy in the U.S. corporate landscape, consistent with governance best practices aimed at aligning director incentives with shareholder returns.
• The vesting schedule over 12 months is a typical short-to-medium term vesting period for such grants, comparable to similar equity awards seen at medical technology companies like Medtronic (MDT) or Boston Scientific (BSX) for their board members, though specific terms vary by company size and compensation philosophy.

Corporate Governance

Related Party Transactions

• The transaction involves an equity grant from NeuroPace Inc. to Renee Ryan, a director of the company, which is a standard form of compensation for an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's financial interests with those of the shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting general employees, the compensation structure for leadership can influence overall company culture and compensation philosophies.

Next Steps

• The granted stock options will vest in twelve equal consecutive monthly installments, subject to Renee Ryan's continuous service.

Key Dates

Keywords

NeuroPace, NPCE, Form 4, stock option, equity grant, director compensation, insider transaction, beneficial ownership